bioAffinity Technologies, Inc.

BIAF · Nasdaq · SIC 8731: Services-Commercial Physical & Biological Research
148
SEC Filings

Business Summary

PART I Business Overview We develop noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Our first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. CyPath Lung addresses the need for noninvasive d...

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionBIAFdiscussed_in_filing Artificial Intelligence
topic_mentionBIAFdiscussed_in_filing Cybersecurity
topic_mentionBIAFdiscussed_in_filing Trusted Computing
topic_mentionBIAFdiscussed_in_filing Blockchain & Crypto
topic_mentionBIAFdiscussed_in_filing Regulation
topic_mentionBIAFdiscussed_in_filing Automotive
topic_mentionBIAFdiscussed_in_filing Healthcare & Bio
topic_mentionBIAFdiscussed_in_filing Platform & Ecosystem
topic_mentionBIAFdiscussed_in_filing Sovereign & Government
topic_mentionBIAFdiscussed_in_filing Artificial Intelligence
topic_mentionBIAFdiscussed_in_filing Cybersecurity
topic_mentionBIAFdiscussed_in_filing Trusted Computing
topic_mentionBIAFdiscussed_in_filing Blockchain & Crypto
topic_mentionBIAFdiscussed_in_filing Regulation
topic_mentionBIAFdiscussed_in_filing Automotive
topic_mentionBIAFdiscussed_in_filing Healthcare & Bio
topic_mentionBIAFdiscussed_in_filing Platform & Ecosystem
topic_mentionBIAFdiscussed_in_filing Sovereign & Government
topic_mentionBIAFdiscussed_in_filing Artificial Intelligence
topic_mentionBIAFdiscussed_in_filing Cybersecurity

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-162025-12-310001493152-26-010143EDGAR74K words
2025-03-312024-12-310001641172-25-001840EDGAR
2024-04-012023-12-310001493152-24-012358EDGAR
2023-03-312022-12-310001493152-23-010186EDGAR

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-142025-09-300001493152-25-023405EDGAR27K words
2025-08-142025-06-300001641172-25-024163EDGAR
2025-05-152025-03-310001641172-25-010787EDGAR
2024-11-142024-09-300001493152-24-045954EDGAR
2024-08-142024-06-300001493152-24-031943EDGAR
2024-05-152024-03-310001493152-24-019615EDGAR
2023-11-142023-09-300001493152-23-040986EDGAR
2023-08-142023-06-300001493152-23-028453EDGAR
2023-05-152023-03-310001493152-23-017083EDGAR
2022-11-142022-09-300001493152-22-032248EDGAR

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-04-010001493152-26-014653EDGAR1K words
2026-03-260001493152-26-012808EDGAR
2026-03-250001493152-26-012683EDGAR
2026-03-170001493152-26-010584EDGAR
2026-03-130001493152-26-009986EDGAR
2026-03-100001493152-26-009463EDGAR
2026-03-060001493152-26-009154EDGAR
2026-03-030001493152-26-008723EDGAR
2026-02-250001493152-26-007965EDGAR
2026-02-190001493152-26-007464EDGAR

148 total filings indexed. 124 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

ABSI — Absci Corp CRL — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CBIH — Cannabis Bioscience International Holdings, Inc. FOXO — FOXO TECHNOLOGIES INC. INCY — INCYTE CORP IQV — IQVIA HOLDINGS INC. NOTV — Inotiv, Inc. MXCT — MAXCYTE, INC.

Company Identity

CIK0001712762
TickerBIAF
ExchangeNasdaq
SIC8731: Services-Commercial Physical & Biological Research
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 3eeb8319f79655374bce51df7b94dd3543a899ea5d458631424834ff0089bc2f
parent: c8a77457e0b215cdf23d3f5d76f35463b06f18432a519a121022380cb8b963de
content hash: 991f75eaa434a031c98c299394e46764d0562f6ddfaabbe86b64175bd55ae586
signed: 2026-04-13T04:43:57.939Z
sources: 14 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf